Bimatoprost

Sarah M. Michienzi, PharmD, PGY-2 HIV/ID

• Specialty Resident, Section of Infectious Diseases, Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois

https://pharmacy.uic.edu/profiles/msarah/

Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women symptoms 2015 flu bimatoprost 3 ml discount. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism medicine valley high school buy 3 ml bimatoprost with mastercard. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women symptoms stiff neck bimatoprost 3 ml buy without a prescription. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis medicine and manicures bimatoprost 3 ml buy free shipping. In women treatment 20 initiative bimatoprost 3 ml on line, testosterone also is the principal androgen and is synthesized in the corpus luteum and the adrenal cortex by similar pathways. Secretion and Transport of Testosterone Testosterone secretion is greater in men than in women at almost all stages of life, a difference that explains many of the other differences between men and women. The testosterone value falls again in the first few days after birth, but it rises and peaks again at about 250 ng/dL at 2­3 months after birth and falls to less than 50 ng/dL by 6 months, where it remains until puberty. During puberty, from about 12 to 17 years of age, the serum testosterone concentration in males increases so that by early adulthood the serum testosterone concentration is 300 ng/dL to 800 ng/dL in men, compared to 30 ng/dL to 50 ng/dL in women. The magnitude of the testosterone concentration in the male is responsible for the pubertal changes that further differentiate men from women. As men age, their serum testosterone concentrations gradually decrease, which may contribute to other effects of aging in men. Testosterone secretion is likewise pulsatile and diurnal, the highest plasma concentrations occurring at about 8 am and the lowest at about 8 pm. Albumin binds almost 60% of circulating testosterone with low affinity, leaving about 2% unbound or free. Physiological and Pharmacological Effects of Androgens Testosterone is the principal circulating androgen in men. At least three mechanisms contribute to the varied effects of testosterone: testosterone to dihydrotestosterone. The enzyme complex aromatase, present in many tissues, catalyzes the conversion of testosterone to estradiol. This conversion accounts for about 85% of circulating estradiol in men; the remainder is secreted directly by the testes (MacDonald et al. Dihydrotestosterone is metabolized to androsterone, androstanedione, and androstanediol. Thus, androgens and estrogens are synthesized; corticosterone and cortisol are not formed. The result is very mild androgen resistance, manifest principally by gynecomastia, and progressively severe motor neuron atrophy (Dejager et al. In some patients resistant to standard androgen deprivation therapy, the tumor responds to further depletion of androgens by inhibitors of adrenal androgen synthesis, such as abiraterone. The ligand-receptor complex recruits coactivators and acts as a transcription factor complex, stimulating or repressing expression of those genes (Agoulnik and Weigel, 2008). Administration of estradiol corrects the bone abnormalities in patients with aromatase deficiency but not in those with an estrogenreceptor defect. This paradigm demonstrated that the increase in sexual desire and erectile function and decrease in subcutaneous and abdominal fat require conversion of testosterone to estradiol but that the increase in lean mass and muscle strength do not (Finkelstein et al. In the anlage of the external genitalia, testosterone is converted to dihydrotestosterone, which causes the development of the male external genitalia. The increase in testosterone at the end of gestation may result in further phallic growth. During Fetal Development Testosterone deficiency in a male fetus during the first trimester in utero causes incomplete sexual differentiation. Complete deficiency of testosterone secretion results in entirely female external genitalia. Testosterone deficiency at this stage of development also leads to failure of the Wolffian ducts to differentiate into the male internal genitalia, but the Müllerian ducts do not differentiate into the female internal genitalia as long as testes are present and secrete Müllerian inhibitory substance. The most severe form results in complete absence of androgen action and a female phenotype; moderately severe forms result in partial virilization of the external genitalia; and the mildest forms permit normal virilization in utero and result only in impaired spermatogenesis in adulthood (McPhaul and Griffin, 1999). Abnormal 5-reductase results in incomplete virilization of the external genitalia in utero but normal development of the male internal genitalia, which requires only testosterone (Wilson et al. Infancy the consequences of the increase in testosterone secretion by the testes during the first few months of life are not yet known. Increased secretion of testosterone into the systemic circulation affects many tissues simultaneously, and the changes in most of them occur gradually during the course of several years. The phallus enlarges in length and width, the scrotum becomes rugated, and the prostate begins secreting the fluid it contributes to the semen. The skin becomes coarser and oilier due to increased sebum production, which contributes to the development of acne. Sexual hair begins to grow, initially pubic and axillary hair, then hair on the lower legs, and finally other body hair and facial hair. Muscle mass and strength, especially of the shoulder girdle, increase, and subcutaneous fat decreases. Epiphyseal bone growth accelerates, resulting in the pubertal growth spurt, but epiphyseal maturation leads eventually to slowing and then cessation of growth. Erythropoiesis increases, resulting in higher hematocrit and hemoglobin concentrations in men than boys or women. Other changes may result from the increase in testosterone during puberty; men tend to have a better sense of spatial relations than do women and to exhibit behavior that differs in some ways from that of women, including being more aggressive. All of the pubertal changes previously described, including those of the external genitalia, sexual hair, muscle mass, voice, and behavior, are impaired to a degree proportionate to the abnormality of testosterone secretion. In addition, if growth hormone secretion is normal when testosterone secretion is subnormal during the years of expected puberty, the long bones continue to lengthen because the epiphyses do not close. Another consequence of subnormal testosterone secretion during the age of expected puberty is enlargement of glandular breast tissue, called gynecomastia. Adulthood the serum testosterone concentration and the characteristics of the adult man are maintained largely during early adulthood and midlife. One change during this time is the gradual development of male pattern baldness, beginning with recession of hair at the temples or at the vertex. One is benign prostatic hyperplasia, which occurs to a variable degree in almost all men, sometimes obstructing urine outflow by compressing the urethra as it passes through the prostate. Although no direct evidence suggests that testosterone causes the disease, prostate cancer depends on androgen stimulation. This dependency is the basis of treating metastatic prostate cancer by lowering the serum testosterone concentration or by blocking its action at the receptor. After Completion of Puberty When testosterone secretion becomes impaired after puberty. When the degree of testosterone deficiency is substantial, libido and energy decrease within a week or two, but other testosterone-dependent characteristics decline more slowly. A clinically detectable decrease in muscle mass in an individual does not occur for several years. A pronounced decrease in hematocrit and hemoglobin will occur within several months. A decrease in bone mineral density probably can be detected by dual-energy absorptiometry within 2 years, but an increase in fracture incidence would not be likely to occur for many years. This fall in serum testosterone could contribute to several other changes that occur with increasing age in men, including decreases in energy, libido, muscle mass and strength, and bone mineral density, as well as increased fat mass and fractures. Androgen deprivation also leads to insulin resistance, truncal obesity, and abnormal serum lipids, as observed in patients with metastatic prostate cancer receiving this treatment (see also Chapter 68). In Women Loss of androgen secretion in women results in a decrease in sexual hair, but not for many years. Androgens may have other important effects in women, and the loss of androgens (especially with the severe loss of ovarian and adrenal androgens that occurs in panhypopituitarism) may result in the loss of effects associated with libido, energy, muscle mass and strength, and bone mineral density. Therapeutic Androgen Preparations Ingestion of testosterone is not an effective means of replacing testosterone deficiency due to the rapid hepatic catabolism. Most pharmaceutical preparations of androgens, therefore, are designed to bypass hepatic catabolism of testosterone. Consequences of Androgen Deficiency the consequences of androgen deficiency depend on the stage of life during which the deficiency first occurs and on the degree of the deficiency. Consequently, 17-alkylated androgens are androgenic when administered orally; however, they are less androgenic than testosterone and cause hepatotoxicity, whereas native testosterone does not. Some 17-alkylated androgens show greater anabolic effects than androgenic effects compared to native testosterone in laboratory tests in rats; however, these "anabolic" steroids, so favored by athletes to illicitly improve performance, have not been convincingly demonstrated to have such a differential effect in human beings. Attempts to decrease the frequency of injections by increasing the amount of each injection result in wider fluctuations and poorer therapeutic outcomes. The undecanoate ester of testosterone, when dissolved in oil and ingested orally, is absorbed into the lymphatic circulation, thus bypassing initial hepatic catabolism. Testosterone undecanoate in oil also can be injected and produces stable serum testosterone concentrations for 2 months. A 2000 Serum Testosterone (ng/dL) Transdermal Delivery Systems To avoid the "first-pass" inactivation of testosterone by the liver, chemicals called excipients are used to facilitate the absorption of native testosterone across the skin in a controlled fashion. These transdermal preparations provide more stable serum testosterone concentrations than do injections of testosterone esters. Selective Androgen Receptor Modulators Selective estrogen receptor modulators have been developed (see Chapter 44). Therapeutic Uses of Androgens Male Hypogonadism the best established indication for administration of androgens is testosterone deficiency in men. Any of the testosterone preparations or testosterone esters described can be used to treat testosterone deficiency. Therefore, measuring the serum testosterone concentration during treatment is the most important aspect of monitoring testosterone treatment for efficacy. With testosterone gels, the serum testosterone concentration is relatively constant from one application to the next (Swerdloff et al. When the enanthate or cypionate ester of testosterone is administered once every 2 weeks, the serum testosterone concentration measured midway between doses should be normal; if not, the dosage schedule should be adjusted accordingly. Normalization of the serum testosterone concentration induces normal virilization in prepubertal boys and restores virilization in adult men who became hypogonadal as adults. Within a few months, and often sooner, libido, energy, and hematocrit return to normal. Several studies demonstrated that testosterone treatment of older men with low testosterone increased their muscle mass and decreased their fat mass. A new study of 788 men 65 years or older with low testosterone concentrations demonstrated that testosterone treatment, compared to placebo, for 1 year improved sexual function, mood, and depressive symptoms (Snyder et al. No studies to date have been large enough to determine if testosterone treatment of older men will increase the risk of prostate cancer, urinary tract symptoms, or heart disease. In a study of women with low serum testosterone concentrations due to panhypopituitarism, increasing the testosterone concentration to normal was associated with small increases in bone mineral density, fat-free mass, and sexual function compared to placebo (Miller et al. Enhancement of Athletic Performance Some athletes take drugs, including androgens, in an attempt to improve their performance. Because androgens for this purpose usually are taken surreptitiously, information about their possible effects is not as complete as that for androgens taken for treatment of male hypogonadism. Monitoring for Deleterious Effects Testosterone administered by itself as a transdermal preparation has no "side effects". Modified testosterone compounds, such as the 17-alkylated androgens, do have undesirable effects even when dosages are targeted at physiological replacement. Some of these undesirable effects occur shortly after testosterone administration is initiated, whereas others usually do not occur until administration has been continued for many years. Raising the serum testosterone concentration can result in undesirable effects similar to those that occur during puberty, including acne, gynecomastia, and more aggressive sexual behavior. Physiological amounts of testosterone do not appear to affect serum lipids or apolipoproteins. Replacement of physiological levels of testosterone occasionally may have undesirable effects in the presence of concomitant illnesses. If the testosterone dose is excessive, erythrocytosis and, uncommonly, salt and water retention and peripheral edema occur even in men who have no predisposition to these conditions. When a man is more than 40 years of age, he is subject to certain testosterone-dependent diseases, including benign prostatic hyperplasia and prostate cancer. The principal adverse effects of the 17-alkylated androgens are hepatic, including cholestasis and, uncommonly, peliosis hepatitis, blood-filled hepatic cysts. Kinds of Androgens Used Virtually all androgens produced for human or veterinary purposes have been taken by athletes. When such use by athletes began more than 30 years ago, 17-alkylated androgens and other compounds (the so-called anabolic steroids) that were thought to have greater anabolic effects than androgen effects relative to testosterone were used most commonly. Consequently, the height and growth hormone status of the boy being treated must be considered. Boys who are short because of growth hormone deficiency should be treated with growth hormone before their hypogonadism is treated with testosterone. In one controlled study, 43 normal young men were randomized to one of four groups: strength training with or without 600 mg of testosterone enanthate once a week (more than six times the replacement dose) or no exercise with or without testosterone. The men who received testosterone experienced an increase in muscle strength compared to those who received placebo, and the men who exercised simultaneously experienced even greater increases (Bhasin et al. There was a dose-dependent effect of testosterone on muscle strength (Bhasin et al. In contrast, in a double-blind study of androstenedione, men who took 100 mg three times a day for 8 weeks did not experience an increase in muscle strength compared to men who took placebo. The treatment also did not increase the mean serum testosterone concentration (King et al. The disease is caused by hereditary impairment of C1-esterase inhibitor or acquired development of antibodies against it. In children, virilization and premature epiphyseal closure prevent chronic use of androgens for prophylaxis, although they are used occasionally to treat acute episodes. Alternatively, concentrated C1-esterase inhibitor derived from human plasma may be used for protection in patients with hereditary angioedema.

Current and future pharmacological treatments for diarrheapredominant irritable bowel syndrome medicine cups buy discount bimatoprost 3 ml on line. The migrating motor complex: control mechanisms and its role in health and disease treatment 6 month old cough order cheap bimatoprost on-line. Efficacy and safety of prucalopride in adults and children with chronic constipation medicine pictures buy generic bimatoprost 3 ml. A review of olanzapine as an antiemetic chemotherapyinduced nausea and vomiting and in palliative care patients symptoms kidney cancer discount bimatoprost 3 ml free shipping. Recent findings on the mode of action of laxatives: the role of platelet activating factor and nitric oxide medications zyprexa generic bimatoprost 3 ml otc. Somatostatin and octreotide on the treatment of acute pancreatitis-basic and clinical studies for three decades. Systematic review of stimulant and nonstimulant laxatives for the treatment of functional constipation. Domperidone: review of pharmacology and clinical applications in gastroenterology. Role of enteric neurotransmission in host defense and protection of the gastrointestinal tract. Primary biliary cirrhosis: safety and benefits of established and emerging therapies. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21st century. Advances in the management of constipation-predominant irritable syndrome: the role of linaclotide. Ulcerative colitis is characterized by confluent mucosal inflammation of the colon starting at the anal verge and extending proximally for a variable extent. The inflammation in Crohn disease is not necessarily confluent, frequently leaving "skip areas" of relatively normal mucosa. The transmural nature of the inflammation may lead to fibrosis and strictures or fistula formation. Primary sclerosing cholangitis is a serious but infrequent complication of ulcerative colitis in which inflammation and fibrostenosis occurs in the intra- and extrahepatic biliary tree (Williamson and Chapman, 2014). Regrettably, no agent can reliably accomplish this, and the response of an individual patient to a given drug may be limited and unpredictable. Recently, mucosal healing has become an important therapeutic aim, as opposed to simply the relief of symptoms (Florholmen, 2015). Both diseases are associated with an aberrant immune response to the commensal microbiota of the gut in genetically susceptible individuals (Sartor, 2006). Nevertheless, Crohn disease and ulcerative colitis result from distinct pathogenic mechanisms at the level of mucosal immune activation (Xavier and Podolsky, 2007). Histologically, the transmural lesions in Crohn disease exhibit marked infiltration of lymphocytes and macrophages, granuloma formation, and submucosal fibrosis, whereas the superficial lesions in ulcerative colitis have lymphocytic and neutrophilic infiltrates. Our understanding of the pathogenesis of both Crohn disease and ulcerative colitis has increased dramatically in recent years (Kaser et al. The azo linkage in sulfasalazine prevents absorption in the stomach and small intestine, and the individual components are not liberated until colonic bacterial azoreductases cleave the bond for local effect (Peppercorn and Goldman, 1972). Once remission has occurred, lower doses can be considered for maintenance, although increasingly the dose used for induction is continued for maintenance. Many potential sites of action (effects on immune function and inflammation) have been demonstrated in vitro for sulfasalazine and mesalamine (Perrotta et al. The alternative approaches employ mesalamine directly, using either a delayed-release formulation or a pH-sensitive coating. Oral sulfasalazine is effective in patients with mild or moderately active ulcerative colitis, with response rates of 60%­80%. The usual dose is 4 g/d in four divided doses with food; to avoid adverse effects, the dose is increased gradually from an initial dose of 500 mg twice a day. Doses as high as 6 g/d can be used but cause an increased incidence of side effects. For patients with severe colitis, sulfasalazine is of less-certain value, even though it is often added as an adjunct to systemic glucocorticoids. The drug plays a useful role in preventing relapses once remission has been achieved. Because they lack the dose-related side effects of sulfapyridine, the delayed- and pH-dependent formulations can be used to deliver mesalamine with improved safety and tolerability. Topical preparations of mesalamine suspended in a wax matrix suppository or in a suspension enema are effective in active proctitis and distal ulcerative colitis, respectively. They appear to be superior to topical hydrocortisone in this setting, with response rates of 75%­90%. Mesalamine enemas (4 g/60 mL) should be used at bedtime and retained for at least 8 h; the suppository (500 and 1000 mg) should be used two to three times a day with the objective of retaining it for at least 3 h. About 20%­30% of orally administered sulfasalazine (mesalamine prodrug) is absorbed in the small intestine. Much of this is taken up by the liver and excreted unmetabolized in the bile; the rest (~10%) is excreted unchanged in the urine. The remaining 70% reaches the colon, where, if cleaved completely by bacterial enzymes, it generates 400 mg mesalamine for every gram of the parent compound. Thereafter, the individual components of sulfasalazine follow different metabolic pathways. Sulfapyridine is absorbed rapidly from the colon and undergoes extensive hepatic metabolism, including acetylation and hydroxylation, and conjugation with glucuronic acid, prior to excretion in the urine. The acetylation phenotype of the patient determines plasma levels of sulfapyridine and the probability of side effects; rapid acetylators have lower systemic levels of the drug and fewer adverse effects. Only 25% of mesalamine is absorbed from the colon, and most of the drug is excreted in the stool. The small amount that is absorbed is acetylated in the intestinal mucosal wall and liver and then excreted in the urine. The pH-sensitive coatings limit gastric and small intestinal absorption of mesalamine. Acetylated mesalamine can be detected in the circulation within an hour after ingestion, indicating some rapid absorption, although some intact microgranules can later be detected in the colon. Some are dose related, including headache, nausea, and fatigue; these can be minimized by giving the medication with meals or by decreasing the dose. Allergic reactions include rash, fever, Stevens-Johnson syndrome, hepatitis, pneumonitis, hemolytic anemia, and bone marrow suppression. Sulfasalazine reversibly decreases the number and motility of sperm but does not impair female fertility. Sulfasalazine inhibits intestinal folate absorption and is usually administered with folate. Diarrhea appears to be particularly common with olsalazine (occurring in 10%­20% of patients). Mesalamine has been associated with interstitial nephritis; renal function should be monitored in all patients receiving these drugs. Both sulfasalazine and its metabolites cross the placenta but have not been shown to harm the fetus. The newer formulations also appear to be safe in pregnancy, but there have been some safety concerns about dibutyl phthalate, an inactive ingredient in the coating of some formulations, in the context of pregnancy. Mechanism of Action, Pharmacological Properties, and Therapeutic Uses the effects of glucocorticoids on the inflammatory response are numerous (see Chapters 42 and 46). Shown are the interactions among bacterial antigens in the intestinal lumen and immune cells in the intestinal wall. Recruitment of a variety of leukocytes is mediated by activation of resident immune cells, including neutrophils. Cell adhesion molecules such as integrins are important in the infiltration of leukocytes, and novel biological therapeutic strategies aimed at blocking leukocyte recruitment are effective at reducing inflammation. Glucocorticoids induce a reduction in the inflammatory response and symptomatic remission in most patients with Crohn disease, with improvement generally occurring within 5 days of initiating treatment; however, some patients require treatment for several weeks before remission occurs. Glucocorticoids sometimes are used for prolonged periods to control symptoms in corticosteroid-dependent patients, as these patients will often experience a recurrence of their disease as the glucocorticoid is withdrawn. Glucocorticoids are not a safe or practical means to maintain remission in either ulcerative colitis or Crohn disease due to the high rate of adverse events associated with their prolonged use. The most commonly used glucocorticoid in Crohn disease is prednisone, given orally or intravenously. For more severe cases, glucocorticoids such as methylprednisolone or hydrocortisone are given intravenously. The red N atoms indicate the diazo linkage that is cleaved to generate the active moiety. The enteric-release form of the synthetic steroid, budesonide, is used for ileocecal Crohn disease. Its putative action is the delivery of therapeutic quantities of steroid to a specific portion of inflamed gut while minimizing systemic side effects, owing to its local release and extensive first-pass hepatic metabolism to inactive derivatives such that systemic levels remain low. Generally, however, oral budesonide is considered less effective than conventional glucocorticoids. Glucocorticoid enemas are useful mainly in patients whose disease is limited to the rectum and left colon. Absorption, although less than with oral preparations, is still substantial (up to 50%­75%). Hydrocortisone also can be given once or twice daily as a 10% foam suspension that delivers 80 mg hydrocortisone per application; this formulation can be useful in patients with very short areas of distal proctitis and difficulty retaining enemas. Prednisone is most often administered orally but can be administered intravenously when patients present with severe, acute flares of disease. Most patients respond within 10­14 days, at which point the dose is reduced by 5 mg per week (tapered) over several weeks to months. Prednisone is absorbed at a rate of 50%­90%; 65%­90% of the absorbed drug is protein bound in the serum. Because of the complex nature of the mechanism of action of glucocorticoids, numerous drug interactions have been reported. The bioavailability of orally administered budesonide is limited (9%­21%) by its high first-pass metabolism. These are numerous, but among the more common are skin and soft tissue manifestations, including skin thinning and the development of Cushingoid features (weight redistribution and weight gain). Other side effects include cardiovascular events and psychiatric and cognitive effects. This effect necessitates the tapering of dose rather than quick withdrawal of the drug. The mechanisms underlying these and other adverse effects of conventional glucocorticoids are detailed in Chapter 46. Budesonide has a similar profile of adverse events, but with lower incidence due its extensive first-pass hepatic metabolism. However, their potential for serious adverse effects mandates a careful assessment of risks and benefits in each patient. These drugs are generally used interchangeably with appropriate dose adjustments, typically azathioprine (1. They help maintain remission in both diseases; they also may prevent or delay recurrence of Crohn disease after surgical resection. The clinical response to azathioprine or mercaptopurine may take weeks to months, such that other drugs with a more rapid onset of action. Thus, these purines are used in glucocorticoid-unresponsive or glucocorticoiddependent disease and in patients who have had recurrent flares of disease requiring repeated courses of steroids. In addition, patients who have not responded adequately to mesalamine but are not acutely ill may benefit by conversion from glucocorticoids to immunomodulatory drugs. In addition, relative to normal metabolizers, the 6-thioguanine levels of these rapid metabolizers are lower for an equivalent oral dose, possibly reducing therapeutic response. Xanthine oxidase in the small intestine and liver converts mercaptopurine to thiouric acid, which has no therapeutic activity. Thus, patients on mercaptopurine should be warned about potentially serious interactions with medications used to treat gout or hyperuricemia, and the dose should be decreased to 25% of the standard dose in subjects who are already taking allopurinol. Adverse effects of azathioprine-mercaptopurine can be either idiosyncratic or dose related. Adverse effects occur at any time after initiation of treatment and can affect up to 10% of patients. One of the most serious idiosyncratic reactions is pancreatitis, which affects about 5% of patients treated with these drugs. Fever, rash, and arthralgias are seen occasionally; nausea and vomiting are somewhat more frequent. The major dose-related adverse effect is bone marrow suppression, and blood counts should be monitored closely when therapy is initiated and at less-frequent intervals during maintenance therapy. Thiopurines given in the setting of cancer chemotherapy or organ transplants have been associated with an increased incidence of malignancy, particularly non-Hodgkin lymphoma. Favorable responses to azathioprine-mercaptopurine are seen in up to two-thirds of patients. The relative activities of these different pathways may explain, in part, individual variations in efficacy and adverse effects. The anti-inflammatory effects of methotrexate may involve mechanisms in addition to inhibition of dihydrofolate reductase. In Crohn disease, it is used for maintenance of remission and as an adjunct to biologics to boost efficacy and reduce formation of antidrug antibodies (Patel et al.

Folate deficiency is implicated in the incidence of neural tube defects (Wallingford et al medications heart failure bimatoprost 3 ml free shipping. An inadequate intake of folate also can result in elevations in plasma homocysteine treatment brown recluse spider bite generic bimatoprost 3 ml buy on-line. Because even moderate hyperhomocysteinemia is considered an independent risk factor for coronary artery and peripheral vascular disease and for venous thrombosis medications heart disease cheap bimatoprost, the role of folate as a methyl donor in the homocysteine-to-methionine conversion is receiving increased attention (Stanger and Wonisch treatment 4 syphilis buy cheap bimatoprost 3 ml online, 2012) medications for bipolar disorder buy bimatoprost in india. The therapeutic use of folic acid is lim- containing PteGlu or l-methylfolate, as an aqueous solution for injection (5 mg/mL), and in combination with other vitamins and minerals. Folinic acid (leucovorin calcium, citrovorum factor) is the 5-formyl derivative of tetrahydrofolic acid. The principal therapeutic uses of folinic acid are to circumvent the inhibition of dihydrofolate reductase as a part of high-dose methotrexate therapy and to potentiate fluorouracil in the treatment of colorectal cancer (see Chapter 66). It also has been used as an antidote to counteract the toxicity of folate antagonists such as pyrimethamine or trimethoprim. Folinic acid provides no advantage over folic acid, is more expensive, and therefore is not recommended. A single exception is the megaloblastic anemia associated with congenital dihydrofolate reductase deficiency. Evaluation of the serum folate level can help exclude folate deficiency, but only in patients whose serum folate levels exceed 5. Red cell folate levels (reference range > 140 ng/mL) reflect chronic folate levels, are less affected by acute ingestion of folate than are serum levels, but are more time consuming and costly to measure. Serum folate concentrations more frequently show a higher correlation with serum homocysteine, which is a sensitive marker of deficiency (Farrell et al. In any case, a patient with a low serum or red cell folate level should have follow-up tests that include serum homocysteine (reference range 5­16 mmol/L), which is elevated in B12 and folate deficiency, and serum methylmalonic acid (reference range 70­270 mmol/L), which is elevated only in B12 deficiency. There have been rare reports of reactions to parenteral injections of folic acid and leucovorin. Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin, and primidone and increase the frequency of seizures in susceptible children. As with vitamin B12 therapy, effective use of the vitamin depends on accurate diagnosis and an understanding of the mechanisms that are operative in a specific disease state. The following general principles of therapy should be respected: Dietary supplementation is necessary when there is a requirement that may not be met by a "normal" diet. The daily ingestion of a multivitamin preparation containing 400­500 g of folic acid has become standard practice before and during pregnancy to reduce the incidence of neural tube defects and for as long as a woman is breastfeeding. In women with a history of a pregnancy complicated by a neural tube defect, an even larger dose of 4 mg/d has been recommended. Patients on total parenteral nutrition should receive folic acid supplements as part of their fluid regimen because liver folate stores are limited. The 1-mg dose also has been used in the treatment of patients with elevated levels of homocysteine. Multivitamin preparations should be avoided unless there is good reason to suspect deficiency of several vitamins. The administration of large doses of folic acid can result in an apparent improvement of the megaloblastic anemia, inasmuch as PteGlu is converted by dihydrofolate Bibliography Agarwal R. Safety and efficacy of total dose infusion of 1020 mg of ferumoxytol administered over 15 min. Iron sucrose-characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and irondeficiency anemia in a broad range of therapeutic areas. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. Erythropoetin or darbepoetin for patients with cancer: meta-analysis based on individual patient data. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after highdose chemotherapy and autologous bone marrow transplantation. Molecular pathogenesis of Wilson and Menkes disease: correlation of mutations with molecular defects and disease phenotypes. Review of trace mineral requirements for preterm infants: what are the current recommendations for clinical practice Human interleukin 7: molecular cloning and growth factor activity on human and murine B-lineage cells. Successful autologous transplantation of blood stem cells mobilized with recombinant human granulocyte-macrophage colonystimulating factor. The use of radioactive isotopes in the study of iron and hemoglobin metabolism and the physiology of the erythrocyte. Safety issues with intravenous iron products in the management of anemia in chronic kidney disease. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. American Society of Hematology and the American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Disorders of cobalamin (vitamin B12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. Enzymatic and non-enzymatic antioxidative effects of folic acid and its reduced derivates. The continuing challenge of understanding, preventing, and treating neural tube defects. The isolation of the vitamin B12 coenzyme and the role of the vitamin in methionine synthesis. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Agents Affecting Mineral Ion Homeostasis and Bone Turnover / 887 this page intentionally left blank 42 Chapter Introduction to Endocrinology: the Hypothalamic-Pituitary Axis Mark E. The major functions of hormones include the regulation of energy storage, production, and utilization; the adaptation to new environments or conditions of stress; the facilitation of growth and development; and the maturation and function of the reproductive system. Although hormones were originally defined as products of ductless glands, we now appreciate that many organs not classically considered as "endocrine". In addition, the field of endocrinology has expanded to include the actions of growth factors acting by means of autocrine and paracrine mechanisms, the influence of neurons-particularly those in the hypothalamus-that regulate endocrine function, and the reciprocal interactions of cytokines and other components of the immune system with the endocrine system. Conceptually, hormones may be divided into two classes: Hormones that act predominantly via nuclear receptors to modulate transcription in target cells. The Hypothalamic-Pituitary-Endocrine Axis Many of the classic endocrine hormones. Discrete sets of hypothalamic neurons produce different releasing and inhibiting hormones, which are axonally transported to the median eminence. On stimulation, these neurons secrete their respective hypothalamic hormones into the hypothalamic-adenohypophyseal portal veins, which connect to the anterior pituitary gland. The hypothalamic hormones bind to membrane receptors on specific subsets of pituitary cells and regulate the secretion of the corresponding pituitary hormones. The pituitary hormones, which can be thought of as the master signals, circulate to the target endocrine glands or other tissues, where they activate specific receptors to stimulate the synthesis and secretion of the target endocrine hormones or exert other tissue-specific effects. These interactions are feed-forward regulation in which the master (signal) hormones stimulate the production of target hormones by the endocrine organs. Typically, the endocrine target hormone circulates to both the hypothalamus and pituitary, where it acts via specific receptors to inhibit the production and secretion of both its hypothalamic-releasing hormone and the regulatory pituitary hormone. In addition, other brain regions have inputs to the hypothalamic hormone­producing neurons, further integrating the regulation of hormone levels in response to diverse stimuli. They secrete hypothalamic releasing hormones, which reach the anterior pituitary via the hypothalamicadenohypophyseal portal system and stimulate distinct populations of pituitary cells. These cells, in turn, secrete the trophic (signal) hormones, which regulate endocrine organs and other tissues. Arginine vasopressin plays an important role in water homeostasis (see Chapter 25); oxytocin plays important roles in labor and parturition and in milk letdown, as discussed in the sections that follow. Ghrelin is synthesized predominantly in endocrine cells in the fundus of the stomach but also is produced at lower levels at a number of other sites, including the pituitary and hypothalamus. Thus, sleep, stress, hypoglycemia, exercise, and estrogen increase the secretion of both hormones. The signal transduction pathway for the insulin receptor is described in detail in Chapter 47. This response is distinct from milk letdown, which is mediated by oxytocin release from the posterior pituitary gland. These receptors contain an extracellular hormone-binding domain, a single membrane-spanning region, and an intracellular domain that mediates signal transduction. These interactions induce a conformational change that activates downstream signaling. In addition, soluble forms that correspond to the extracellular domain of the receptor are found in circulation. These adenomas often retain some features of the normal regulation described previously, thus permitting pharmacological modulation of secretion-an important modality in therapy. Pituitary irradiation may be associated with significant long-term complications, including visual deterioration and pituitary dysfunction. Thus, increased attention has been given to the pharmacological management of acromegaly. Mortality is increased at least 2-fold relative to age-matched controls, predominantly due to increased death from cardiovascular disease. In men, hyperprolactinemia causes loss of libido, erectile dysfunction, and infertility. Octreotide exerts pharmacologic actions similar to those of Diagnosis of Growth Hormone and Prolactin Excess. Octreotide (100 g) administered subcutaneously three times daily is 100% bioactive; peak effects are seen within 30 min, serum t1/2 is about 90 min, and duration of action is about 12 h. The "gold standard" diagnostic test for acromegaly is the oral glucose tolerance test. Its efficacy appears comparable to that of the long-acting formulation of octreotide. Gastrointestinal side effects-including diarrhea, nau- Impaired Production Clinical Manifestations of Growth Hormone Deficiency. Approximately 25% of patients receiving these drugs develop multiple tiny gallstones, presumably due to decreased gallbladder contraction and bile secretion. For octreotide and lanreotide, most patients will experience no change in glucose tolerance; however, depending on the relative effects on insulin secretion versus resistance, some patients may experience a worsening and others an improvement in glucose tolerance. Pasireotide, in addition, decreases the secretion of glucagon-like peptide 1 and glucose insulinotropic peptide, two incretins that facilitate insulin secretion and inhibit glucagon secretion. As a result, glucose tolerance usually worsens significantly and antihyperglycemic therapy is often needed. Octreotide is used for treatment of acute variceal bleeding and for perioperative prophylaxis in pancreatic surgery. The oral dose of bromocriptine is well absorbed; however, only 7% of the dose reaches the systemic circulation because of extensive first-pass metabolism in the liver. Bromocriptine has a short elimination t1/2 (between 2 and 8 h) and thus is usually administered in divided doses. To avoid the need for frequent dosing, a slow-release oral form is available outside the U. Hyperprolactinemia and tumor growth recur on cessation of therapy in most patients. At higher concentrations, bromocriptine is used in the management of Parkinson disease (see Chapter 18). Frequent side effects include nausea and vomiting, headache, and postural hypotension, particularly on initial use. The drug is administered subcutaneously as a 40-mg loading dose, followed by administration of 10 mg/d. Pegvisomant should not be used in patients with an unexplained elevation of hepatic transaminases, and liver function tests should be monitored in all patients. Nevertheless, the development of tachyphylaxis due to these antibodies has not been reported. Cabergoline is the preferred drug for the treatment of hyperprolactinemia because of greater efficacy and lower adverse effects. Cabergoline induces remission in a significant number of patients with prolactinomas. Compared to bromocriptine, cabergoline has a much lower tendency to induce nausea, although it still may cause hypotension and dizziness. This has been attributed to the inhibition of the type 1 isozyme of steroid 11-hydroxysteroid dehydrogenase, which normally converts inactive cortisone into the active 11-hydroxy derivative cortisol (see Chapter 46). Other contraindications include proliferative retinopathy or severe nonproliferative diabetic retinopathy. Mecasermin is administered by subcutaneous injection, and absorption is virtually complete.

Regardless of the mechanism medicine 93 3109 bimatoprost 3 ml online, central tolerance has thus far not been exploited for pharmacological intervention symptoms norovirus cheap bimatoprost 3 ml overnight delivery. When an individual is reexposed to the hapten symptoms 6 weeks pregnant discount bimatoprost 3 ml buy on line, antigen-specific T cells migrate to the skin medications given to newborns bimatoprost 3 ml purchase with mastercard, causing local inflammation and edema medications you cant drink alcohol with order generic bimatoprost. Autoimmunity, Immune Deficiency, and Transplant Rejection Just as for a regular and, appropriate immune response, autoimmunity is founded in either humoral (autoantibody) or cellular (T-cell) responses. As described in the section on lymphocyte development, the process of central tolerance limits the development of autoreactive B and T cells. This process is imperfect, and mechanisms of peripheral tolerance are in place to limit the activity of self-reactive lymphocytes that manage to escape thymic deletion. Consequently, Immune Deficiencies Primary immunodeficiency encompasses genetic or developmental defects in the immune system that leave the individual susceptible to infections to various degrees. Severe forms (severe combined immunodeficiency) are typically diagnosed in early childhood and are associated with significantly reduced life expectancy. Presently, nine classes of primary immunodeficiency are recognized, totaling over 120 unique conditions. Unfortunately, current treatment options are limited to supportive therapy in the form of antiviral, antifungal, and antibacterial drugs. Current nomenclature incorporates information on the source of the antibody as well as the intended target tissue. Acquired immunodeficiency refers to the loss of immune function due to environmental exposure. These conditions encompass patients receiving immune-suppressive therapy for autoimmune disorders or to prevent transplant rejections. Acquired immunodeficiency is also commonly observed in patients suffering from hematopoietic malignancies, as tumor cells outcompete functional leukocytes for space in the bone marrow or blood. Immune checkpoints refer to inhibitory (often negative-feedback) pathways that limit the amplitude and duration of an immune response. Under normal physiological conditions, immune checkpoints protect tissues from damage during an immune response and contribute to the maintenance of self-tolerance. In conditions of chronic viral infections and cancers, chronic antigen persistence results in the development of dysfunctional "exhausted" T cells. Exhausted T cells are actively suppressed by inhibitory signals that limit their effector functions and turn off their target cell­ killing capacity. These inhibitory pathways resulting in T-cell exhaustion have been documented in mice, monkeys, and humans, highlighting their importance in modulating T-cell function. Cancer cells express a variety of genetic and epigenetic alterations that distinguish them from their normal counterparts. These tumor-associated antigens can be recognized by the host immune system; antitumor T cells are generated, which then eliminate these transformed cells. One of these evasion strategies involves the manipulation of immune-inhibitory pathways or immune checkpoints. Tumors avoid being destroyed by actively stimulating these inhibitory receptors to turn off antitumor T cells. The intensity of rejection is minimized with increased compatibility between donor and recipient; however, a lifelong regimen of immunosuppressive drugs is unavoidable (see Chapter 35). Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. This older nomenclature, still in use by some workers, focused primarily on the source of the antibody (murine, human, chimeric, or humanized). The therapeutic goal is to interfere with this inhibitory interaction that is actively suppressing T cells in the tumor microenvironment. The tumor effectively inactivates the T cells and the tumor continues to grow (Pardoll, 2012; Tang et al. These pathways are further discussed in the cancer therapy chapters (Chapters 65­68). Immunotherapy to cancers holds great promise for treating patients with advanced disease, as evidenced by the success of clinical trials using this technology. Furthermore, combination strategies that include checkpoint blockade paired with radiation or chemotherapy may further increase responsiveness in cancer patients. One consequence of checkpoint blockade is that autoreactive T cells are also unleashed after therapy. Patients can develop toxicities that include hepatic, pneumonitis, colitis, rash, vitiligo, and endocrine pathology. Greater immunotherapy efficacy will likely be achieved when drugs are developed to target other inhibitory pathways and are used in combination, but caution must be evaluated to ensure patient safety (Callahan et al. Innate immunity turned insideout: antimicrobial defense by phagocyte extracellular traps. Four major classes of immunosuppressive drugs are discussed: glucocorticoids (see Chapter 46), calcineurin inhibitors, antiproliferative and antimetabolic agents (see Chapter 66), and antibodies. While there are similarities, the approach to the use of immunosuppressant drugs in transplant rejection has evolved separately from the approaches used to treat autoimmune disease and thus is presented separately. Immunosuppression Immunosuppressive drugs are used to dampen the immune response in organ transplantation and autoimmune disease. In transplantation, the major classes of immunosuppressive drugs used today are the following: Glucocorticoids Calcineurin inhibitors Antiproliferative/antimetabolic agents Biologicals (antibodies) the Immune Response the immune system evolved to discriminate self from nonself. Innate immunity (natural immunity) is primitive, does not require priming, and is of relatively low affinity, but it is broadly reactive. Adaptive immunity (learned immunity) is antigen specific, depends on antigen exposure or priming, and can be of very high affinity. The two arms of immunity work closely together, with the innate immune system most active early in an immune response and adaptive immunity becoming progressively dominant over time. B lymphocytes make antibodies; T lymphocytes function as helper, cytolytic, and regulatory (suppressor) cells. These cells not only are important in the normal immune response to infection and tumors but also mediate transplant rejection and autoimmunity. Immunoglobulins (antibodies) on the B-lymphocyte surface are receptors for a large variety of specific structural conformations. Once activated by specific antigen recognition, both B and T lymphocytes are triggered to differentiate and divide, leading to release of soluble mediators (cytokines, lymphokines) that perform as effectors and regulators of the immune response. Chapter 34 presents a more detailed view of the immune system at the levels of the molecules, cells, and organs involved in immunity. Table 35­1 summarizes the sites of action of representative immunosuppressants on T-cell activation. These drugs are successful in treating conditions such as acute immune rejection of organ transplants and autoimmune diseases. However, such therapies often require lifelong use and nonspecifically suppress the entire immune system, exposing patients in some instances to higher risks of infection and cancer. The calcineurin inhibitors and daily glucocorticoids, in particular, are nephrotoxic and diabetogenic, respectively, thus restricting their usefulness in a variety of clinical settings. Finally, newer small molecules and antibodies have expanded the arsenal of immunosuppressives. Thus, there are useful pharmacological tools that can substantially limit clonal expansion and potentially promote tolerance (Goldfarb-Rumyantzev et al. General Approach to Organ Transplantation Therapy Organ transplantation therapy is organized around five general principles. Employ multitier immunosuppressive therapy; simultaneously use several agents, each of which is directed at a different molecular target within the allograft response. Employ intensive induction and lower-dose maintenance drug protocols; greater immunosuppression is required to gain early engraftment or to treat established rejection than to maintain long-term immunosuppression. Investigation of each episode of transplant dysfunction is required, including evaluation for recurrence of the disease, rejection, drug toxicity, and infection (keeping in mind that these various problems can and often do coexist). Reduce dosage or withdraw a drug if its toxicity exceeds its benefit (Danovitch et al. Biological Induction Therapy In many transplant centers, induction therapy with biological agents is used to delay the use of the nephrotoxic calcineurin inhibitors or to intensify the initial immunosuppressive therapy in patients at high risk of rejection. Most limitations of murine-based mAbs generally were overcome by the introduction of chimeric or humanized mAbs that lack antigenicity and have a prolonged serum t1/2. Antibodies derived from transgenic mice carrying human antibody genes are labeled "humanized" (90%­95% human) or "fully human" (100% human); antibodies derived from human cells are labeled "human. Chimeric antibodies generally contain about 33% mouse protein and 67% human protein and can still produce an antibody response that results in reduced efficacy and shorter t1/2 compared to humanized antibodies. Biological agents for induction therapy in the prophylaxis of rejection currently are used in about 70% of de novo transplant patients. Biological agents for induction can be divided into two groups: the depleting agents and the immune modulators. Maintenance Immunotherapy Basic immunosuppressive therapy uses multiple drugs simultaneously, typically a calcineurin inhibitor, glucocorticoids, and mycophenolate (a purine metabolism inhibitor), each directed at a discrete step in T-cell activation (Vincenti et al. Glucocorticoids, azathioprine, cyclosporine, tacrolimus, mycophenolate, sirolimus, belatacept, and various mAbs and polyclonal antibodies all are approved for use in transplantation. Therefore, treatment of established rejection requires the use of agents directed against activated T cells. Tacrolimus Glucocorticoids the introduction of glucocorticoids as immunosuppressive drugs in the 1960s played a key role in making organ transplantation possible. Prednisone, prednisolone, and other glucocorticoids are used alone and in combination with other immunosuppressive agents for treatment of transplant rejection and autoimmune disorders. Because of perceived slightly greater efficacy and ease of blood level monitoring, tacrolimus has become the preferred calcineurin inhibitor in most transplant centers (Ekberg et al. Like cyclosporine, tacrolimus inhibits T-cell Mechanism of Action Glucocorticoids have broad anti-inflammatory effects on multiple components of cellular immunity, but relatively little effect on humoral immunity. Glucocorticoids bind to receptors inside cells and regulate the transcription of numerous other genes (see Chapter 46). In addition, glucocorticoid-treated neutrophils and monocytes display poor chemotaxis and decreased lysosomal enzyme release. Thus, although the intracellular receptors differ, cyclosporine and tacrolimus target the same pathway for immunosuppression. Tacrolimus is available for oral administration as capsules and Therapeutic Uses There are numerous therapeutic indications for glucocorticoids. They commonly are combined with other immunosuppressive agents to prevent and treat transplant rejection. Lower-dose oral glucocorticoids, however, appear to have different biologic effects; low-dose oral prednisone made optic neuritis worse compared to high-dose intravenous solumedrol (Beck et al. Most transplant centers use an initial high dose of intravenous solumedrol with tapering to a maintenance dose of 5­10 mg/d in the long term. Sublingual tacrolimus has been used off label for the short term in patients who are unable to receive medications orally. Because of intersubject variability in pharmacokinetics, individualized dosing is required for optimal therapy. For tacrolimus, whole blood is the preferred sampling compartment; the trough drug level in whole blood seems to correlate better with clinical events for tacrolimus than for cyclosporine. Target concentrations are 10­15 ng/mL in the early preoperative period and 6­8 ng/mL at 3 months posttransplantation. Target concentrations are dependent on sampling technique and on product-release characteristics, immediate- versus extended-release forms. Plasma protein binding of tacrolimus is 75%­99%, involving primarily albumin and 1-acid glycoprotein. Tacrolimus is indicated for the prophylaxis of Toxicity solid-organ allograft rejection in a manner similar to cyclosporine (see Cyclosporine) and is used off label as rescue therapy in patients with rejection episodes despite "therapeutic" levels of cyclosporine. These dosages are intended to achieve typical blood trough levels in the 5- to 20-ng/mL range (Goring et al. Note that the oral dose of tacrolimus depends on product release characteristics (immediate- vs. Extensive glucocorticoid use often results in disabling and life-threatening adverse effects. These effects include growth retardation in children, avascular necrosis of bone, osteopenia, increased risk of infection, poor wound healing, cataracts, hyperglycemia, and hypertension (see Chapter 46). The advent of combined glucocorticoid/calcineurin inhibitor regimens has Toxicity. Obese patients, African American or Hispanic transplant recipients, or those with a family history of type 2 diabetes or obesity are especially at risk. As with other immunosuppressive agents, there is an increased risk of secondary tumors and opportunistic infections. Diarrhea and alopecia are common in patients on concomitant mycophenolate therapy. Cyclosporine Cyclosporine (cyclosporin A) is a cyclic polypeptide of 11 amino acids, produced by the fungus Beauveria nivea, that inhibits calcineurin activity (Azzi et al. Because of its potential for nephrotoxicity, tacroli- mus blood levels and renal function should be monitored closely. Coadministration with cyclosporine results in additive or synergistic nephrotoxicity; therefore, a delay of at least 24 h is required when switching a patient from cyclosporine to tacrolimus. Per the label, concomitant use of tacrolimus with cyclosporine or sirolimus is not recommended for prophylaxis against renal transplant rejection. Calcineurin phosphatase activity is inhibited after physical interaction with the cyclosporine/cyclophilin complex. At the level of immune system function, cyclosporine suppresses some humoral immunity but is more effective against T-cell­dependent immune mechanisms such as those underlying transplant rejection and some forms of autoimmunity.

Purchase bimatoprost online from canada. Atlas Genius - The Stone Mill • Visulite Theatre • Charlotte NC • 4/23/16.

References

• Hibino N, Tsuchiya K, Sasaki H, et al. Delayed presentation of injury to the sinus of valsalva with aortic regurgitation resulting from penetrating cardiac wounds. J Card Surg. 2003;18:236-239.
• Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 2014;65(2):360- 366.
• Ballert, K., Biggs, G.Y., Isenalumhe, A. Jr, Rosenblum, N., Nitti, V.W. Managing the urethra at transvaginal pelvic organ prolapse repair: a urodynamic approach. J Urol 2009; 181:679-684.
• Wilson AJ, Murphy WA, Hardy DC, Totty WG. Transient osteoporosis: transient bone marrow edema? Radiology 1988; 167(3):757-60.
• West J, Fagan K, Steudel W, et al: Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle, Circ Res 94(8):1109-1114, 2004.
• Greer BE, Koh WJ, Abu-Rustum NR, et al. Cervical cancer: Clinical practice guidelines in oncology. JNCCN. 2010;8(12):1388-1416.
• Lipponen P, Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis, J Pathol 173:333n339, 1994.
• Senagore AJ, Duepree HJ, Delaney CP, Brady KM, Fazio VW. Results of a standardized technique and postoperative care plan for laparoscopic sigmoid colectomy: a 30-month experience. Dis Colon Rectum 2003;46(4):503-509.